Skip to main content

Antibody therapy against coronavirus (COVID-19)

Project description

Antibody therapy against COVID-19

Passive immunotherapy, through the transfer of antibodies, has been proposed as a potential approach for treating patients with COVID-19. Building on previous experience of antibody therapy against SARS- and MERS-CoV, scientists of the EU-funded ATAC project will characterise human antibodies obtained from the blood of recovered coronavirus patients from China and Italy. Using a combination of experimental and computational work, they will optimise, produce and test all antibodies before selecting the most effective candidate for therapy. The rapid dissemination of the project's results will help the medical community respond to the current COVID-19 pandemic through improved patient management.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/coronavirus

Call for proposal

H2020-SC1-PHE-CORONAVIRUS-2020
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

KAROLINSKA INSTITUTET
Address
Nobels Vag 5
17177 Stockholm
Sweden
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 755 396,25

Participants (4)

FONDAZIONE PER L ISTITUTO DI RICERCA IN BIOMEDICINA
Switzerland
EU contribution
€ 1 435 025
Address
Via Vincenzo Vela 6
6500 Bellinzona
Activity type
Research Organisations
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
Belgium
EU contribution
€ 198 545
Address
Rue De La Loi 200
1049 Brussels
Activity type
Research Organisations
TECHNISCHE UNIVERSITAET BRAUNSCHWEIG
Germany
EU contribution
€ 267 323,75
Address
Universitaetsplatz 2
38106 Braunschweig
Activity type
Higher or Secondary Education Establishments
FONDAZIONE IRCCS POLICLINICO SAN MATTEO
Italy
EU contribution
€ 338 750
Address
Viale Golgi 19
27100 Pavia
Activity type
Research Organisations